Tegoprazan-containing Sequential for H. Pylori
ConditionHelicobacter Pylori Infection
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSeoul National University Bundang Hospital
About this trial
As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
congestive heart failure, NYHA III or IV
end-stage renal disease
alcoholics
drug abusers
Trial design
Design model
Parallel
Treatments tested in this trial
Tegoprazan-containing sequential H. pylori eradication therapy
Drugtegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
Esomeprazole-containing sequential H. pylori eradication therapy
DrugEsomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
Treatment groups
400 Participants
are divided into 2 treatment groupsGroup A: Esomeprazole-containing sequential H. pylori eradication therapy (conventional method)Active comparator 1 intervention
Group B: Tegoprazan-containing sequential H. pylori eradication therapy (experimental method)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Eradication rate
Efficacy of H. pylori eradication therapy. confirmed by negative UBT test
Time frame
2 or 3 monthSecondary outcomes
1
Adverse events
any adverse events occured during or after intervention (eradication therapy)
Time frame
up to 6 monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov